Antibiotic substances from Basidiomycetes+. VII. Clitocybe illudens.

M. Anchel,A. Hervey,W. J. Robbins

DOI: https://doi.org/10.1073/PNAS.36.5.300

1950-05-01

Abstract:

What problem does this paper attempt to address?

[Molecular weight characteristics of the proteins of oocytes and of cleavage ova in CBA mice by means of capillary microdisc electrophoresis].

V. Repin,I. Akimova

Tsitologiya

Abstract:5-20 oocytes or cleaving embryos of CBA mice were dissolves in 0.2-0.5 ml of 1% buffered sodium dodecylsulfate (SDS), and soluble proteins were separated using electrophoresis in capillaries filled with PAA-SDS-gel. The method enabled us to calculate the approximate molecular weight of proteins by relative mobilities and allowed to determine 1-5 mmcg protein in a single band. 7 groups of proteins were identified in mouse oocytes using 10% PAA-0.1% SDS-gel with the following molecular weights: 208 000, 206 000, 155 000, 112 000, 59 000, 40 000 and 30 000, resp. The same groups of protein were discovered in zygotes and cleaving mouse embryos. The molecular weight distribution of low-molecular weight basic proteins of CBA mice is species-specific and reveals a qualitative changes in the early embryogenesis.
New and Emerging Therapeutic Drugs for the Treatment of Pulmonary Arterial Hypertension: A Systematic Review

Amir Rasheed,Shadab Aslam,Hafiz Zeeshan Sadiq,Salamat Ali,Rizwana Syed,Binay K Panjiyar

DOI: https://doi.org/10.7759/cureus.68117

2024-08-29

Cureus

Abstract:Pulmonary arterial hypertension (PAH) is a serious, progressive, and potentially fatal lung disease characterized by a gradual increase in mean pulmonary arterial pressure to over 20 mmHg at rest. The pathogenesis of PAH is multifactorial. It involves dynamic obstruction of the pulmonary vasculature through vasoconstriction, structural obstruction due to adverse vascular remodeling, and pathological obstruction caused by vascular fibrosis and stiffening, which reduces compliance. PAH often presents with vague initial symptoms and is frequently diagnosed at an advanced stage. The increased pulmonary arterial pressure leads to vascular remodeling, eventually resulting in right ventricular hypertrophy and failure. PAH is a rare condition with a median life expectancy of three years, underscoring the need for effective treatment alternatives. Several FDA-approved therapeutic options are available, including prostacyclin analogs (epoprostenol, iloprost, and treprostinil), the non-prostanoid IP receptor agonist selexipag, selective endothelin receptor antagonists (ERA) (ambrisentan, bosentan, and macitentan), phosphodiesterase 5 inhibitors (sildenafil and tadalafil), and the soluble guanylate cyclase (sGC) stimulator riociguat. Despite these advancements, current medications do not provide a permanent cure. This study presents an overview of current and emerging PAH therapies through a systematic literature review. It involved an analysis of nine studies and a review of 800 papers from reputable journals published between 2013 and June 2023. The research focused on drug effects on the six-minute walk distance (6-MWD) and associated side effects in randomized controlled trials. The review found that while udenafil, imatinib, racecadotril, sotatercept, anastrozole, riociguat, tacrolimus, and ralinepag were evaluated, imatinib was notably associated with adverse side effects. Conversely, udenafil, racecadotril, sotatercept, anastrozole, riociguat, tacrolimus, and ralinepag were found to be safe, well-tolerated, and effective in improving hemodynamic measures and 6-MWDs. This study aims to summarize the developing treatment options currently under clinical trials, highlighting the need for further trials before their application in clinical practice.
Mechanisms and treatment of pulmonary arterial hypertension

Hossein-Ardeschir Ghofrani,Mardi Gomberg-Maitland,Lan Zhao,Friedrich Grimminger

DOI: https://doi.org/10.1038/s41569-024-01064-4

2024-08-07

Abstract:Substantial progress has been made in the management of pulmonary arterial hypertension (PAH) in the past 25 years, but the disease remains life-limiting. Established therapies for PAH are mostly limited to symptomatic relief by correcting the imbalance of vasoactive factors. The tyrosine kinase inhibitor imatinib, the first predominantly non-vasodilatory drug to be tested in patients with PAH, improved exercise capacity and pulmonary haemodynamics compared with placebo but at the expense of adverse events such as subdural haematoma. Given that administration by inhalation might reduce the risk of systemic adverse effects, inhaled formulations of tyrosine kinase inhibitors are currently in clinical development. Other novel therapeutic approaches for PAH include suppression of activin receptor type IIA signalling with sotatercept, which has shown substantial efficacy in clinical trials and was approved for use in the USA in 2024, but the long-term safety of the drug remains unclear. Future advances in the management of PAH will focus on right ventricular function and involve deep phenotyping and the development of a personalized medicine approach. In this Review, we summarize the mechanisms underlying PAH, provide an overview of available PAH therapies and their limitations, describe the development of newer, predominantly non-vasodilatory drugs that are currently being tested in phase II or III clinical trials, and discuss future directions for PAH research.
Risk stratification and medical therapy of pulmonary arterial hypertension

Nazzareno Galiè,Richard N. Channick,Robert P. Frantz,Ekkehard Grünig,Zhi Cheng Jing,Olga Moiseeva,Ioana R. Preston,Tomas Pulido,Zeenat Safdar,Yuichi Tamura,Vallerie V. McLaughlin

DOI: https://doi.org/10.1183/13993003.01889-2018

IF: 24.3

2019-01-01

European Respiratory Journal

Abstract:Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the availability over the past 15 years of multiple drugs interfering with the endothelin, nitric oxide and prostacyclin pathways. The recent progress observed in medical therapy of PAH is not, therefore, related to the discovery of new pathways, but to the development of new strategies for combination therapy and on escalation of treatments based on systematic assessment of clinical response. The current treatment strategy is based on the severity of the newly diagnosed PAH patient as assessed by a multiparametric risk stratification approach. Clinical, exercise, right ventricular function and haemodynamic parameters are combined to define a low-, intermediate- or high-risk status according to the expected 1-year mortality. The current treatment algorithm provides the most appropriate initial strategy, including monotherapy, or double or triple combination therapy. Further treatment escalation is required in case low-risk status is not achieved in planned follow-up assessments. Lung transplantation may be required in most advanced cases on maximal medical therapy.

respiratory system
Medical Management of Pulmonary Arterial Hypertension: Current Approaches and Investigational Drugs

Qi Jin,Dandan Chen,Xiaochun Zhang,Feng Zhang,Dongxiang Zhong,Dawei Lin,Lihua Guan,Wenzhi Pan,Daxin Zhou,Junbo Ge

DOI: https://doi.org/10.3390/pharmaceutics15061579

IF: 6.525

2023-05-24

Pharmaceutics

Abstract:Pulmonary arterial hypertension (PAH) is a malignant pulmonary vascular syndrome characterized by a progressive increase in pulmonary vascular resistance and pulmonary arterial pressure, which eventually leads to right heart failure and even death. Although the exact mechanism of PAH is not fully understood, pulmonary vasoconstriction, vascular remodeling, immune and inflammatory responses, and thrombosis are thought to be involved in the development and progression of PAH. In the era of non-targeted agents, PAH had a very dismal prognosis with a median survival time of only 2.8 years. With the deep understanding of the pathophysiological mechanism of PAH as well as advances in drug research, PAH-specific therapeutic drugs have developed rapidly in the past 30 years, but they primarily focus on the three classical signaling pathways, namely the endothelin pathway, nitric oxide pathway, and prostacyclin pathway. These drugs dramatically improved pulmonary hemodynamics, cardiac function, exercise tolerance, quality of life, and prognosis in PAH patients, but could only reduce pulmonary arterial pressure and right ventricular afterload to a limited extent. Current targeted agents delay the progression of PAH but cannot fundamentally reverse pulmonary vascular remodeling. Through unremitting efforts, new therapeutic drugs such as sotatercept have emerged, injecting new vitality into this field. This review comprehensively summarizes the general treatments for PAH, including inotropes and vasopressors, diuretics, anticoagulants, general vasodilators, and anemia management. Additionally, this review elaborates the pharmacological properties and recent research progress of twelve specific drugs targeting three classical signaling pathways, as well as dual-, sequential triple-, and initial triple-therapy strategies based on the aforementioned targeted agents. More crucially, the search for novel therapeutic targets for PAH has never stopped, with great progress in recent years, and this review outlines the potential PAH therapeutic agents currently in the exploratory stage to provide new directions for the treatment of PAH and improve the long-term prognosis of PAH patients.

pharmacology & pharmacy
The Future of PAH Treatment

Jennifer L. Keen,Nadine Al-Naamani,Corey E. Ventetuolo

DOI: https://doi.org/10.21693/1933-088x-22.1.55

2023-01-01

Advances in Pulmonary Hypertension

Abstract:Pulmonary arterial hypertension (PAH) is a devastating disease mediated by vasoconstriction and vascular remodeling of the pulmonary vasculature. Current therapies target the imbalance of vasoconstrictors and vasorelaxants in 3 pathways: nitric oxide, prostacyclin, and endothelin. While these have extended lifespans for PAH patients, significant morbidity and mortality remains. Notably, the progress in PAH therapy for over a decade has utilized these same 3 pathways. Fortunately, several new treatment options utilizing different mechanisms are emerging and will be reviewed here.
Endothelial Progenitor Cell-Based Therapy for Pulmonary Arterial Hypertension

Jin-Xiu Yang,Yan-Yun Pan,You-Yang Zhao,Xing-Xiang Wang

DOI: https://doi.org/10.3727/096368912x659899

2013-01-01

Cell Transplantation

Abstract:A growing body of evidence in animal models and clinical studies supports the concept that endothelial progenitor cell (EPC)-mediated therapy ameliorates pulmonary arterial hypertension (PAH) and thus may represent a novel approach to treat it. Conversely, several experimental findings suggest that EPCs may be involved in PAH pathogenesis and disease progression. These discrepant results confuse the application of EPC transplantation as an effective treatment strategy for PAH. To improve the study of EPC transplantation in PAH therapy, it is high time that we resolve this dilemma. In this review, we examine the pathobiological changes of PAH, the characteristics of EPCs, and the underlying mechanisms of EPC effects on PAH.
Pharmacological Update and Emerging Treatments of Pulmonary Hypertension

Shazli Khan,Sukhbir Randhawa,Haris Patail,Yaakov Spira,William H Frishman,Wilbert S Aronow,Gregg M Lanier,William H. Frishman,Wilbert S. Aronow,Gregg M. Lanier

DOI: https://doi.org/10.1097/crd.0000000000000647

2024-01-31

Cardiology in Review

Abstract:Pulmonary hypertension (PH) is defined as elevated pressures in the pulmonary artery and is associated with significant morbidity and mortality. The World Health Organization classifies PH into 5 distinct groups based on underlying etiology, pathology, and modality of treatment. Therapeutic approach may be challenging due to the extensive spectrum of causes and underlying mechanisms mediating PH. The 5 groups include pulmonary arterial hypertension (group 1), PH secondary to left heart disease (group 2), PH secondary to chronic lung disease (group 3), chronic thromboembolic pulmonary hypertension (group 4), and PH due to miscellaneous causes (group 5). Although significant progress has been made in the treatment of group 1 PH, there is a continued need to develop new therapies for all types of PH. Additionally, most treatments currently available improve functional capacity and symptoms but without a significant benefit in mortality. In this review, we aim to describe the various etiologies of PH and their established pharmacotherapies, as well as expand on emerging therapeutic options for each group.

cardiac & cardiovascular systems
Pulmonary arterial hypertension: pharmacologic therapies and potential pulmonary artery denervation treatment.

Yao-Jun Zhang,Ming-Hui Li,Shao-Liang Chen

DOI: https://doi.org/10.4244/EIJV9SRA25

2013-01-01

EuroIntervention

Abstract:Pulmonary arterial hypertension (PAR) is a group of diseases related to progressively increasing pulmonary vascular resistance, a high incidence of right ventricular failure and premature death. Only a limited number of pharmaceutical therapies have proven to be beneficial for PAR. These therapies improve symptoms, exercise capacity, and haemodynamics; however, the clinical relevance of these effects has been challenged. Therefore, the effect of currently approved treatment options remains inconclusive. Conversely, several new drugs for various aetiologies and clinical stages are expected to provide significant advances for the treatment of PAR. Moreover, percutaneous pulmonary artery denervation treatment may lead to a new therapeutic orientation in patients with PAH. The aim of this review is to present the new developments in PAR treatment, provide a brief overview of future directions in the field and discuss the potential future prospects of these innovative therapies.
Pulmonary Hypertension: Pharmacological and Non-Pharmacological Therapies

Jason Tsai,Shaista Malik,Stephanie C. Tjen-A-Looi

DOI: https://doi.org/10.3390/life14101265

2024-10-06

Life

Abstract:Pulmonary hypertension (PH) is a severe and chronic disease characterized by increased pulmonary vascular resistance and remodeling, often precipitating right-sided heart dysfunction and death. Although the condition is progressive and incurable, current therapies for the disease focus on multiple different drugs and general supportive therapies to manage symptoms and prolong survival, ranging from medications more specific to pulmonary arterial hypertension (PAH) to exercise training. Moreover, there are multiple studies exploring novel experimental drugs and therapies including unique neurostimulation, to help better manage the disease. Here, we provide a narrative review focusing on current PH treatments that target multiple underlying biochemical mechanisms, including imbalances in vasoconstrictor–vasodilator and autonomic nervous system function, inflammation, and bone morphogenic protein (BMP) signaling. We also focus on the potential of novel therapies for managing PH, focusing on multiple types of neurostimulation including acupuncture. Lastly, we also touch upon the disease's different subgroups, clinical presentations and prognosis, diagnostics, demographics, and cost.

biology
Recent Advances in the Treatment of Pulmonary Arterial Hypertension

Naoyuki Otani,Takashi Tomoe,Atsuhiko Kawabe,Takushi Sugiyama,Yasuto Horie,Hiroyuki Sugimura,Takanori Yasu,Takaaki Nakamoto,Otani,Tomoe,Kawabe,Sugiyama,Horie,Sugimura,Yasu,Nakamoto

DOI: https://doi.org/10.3390/ph15101277

IF: 4.6

2022-10-18

Pharmaceuticals

Abstract:Pulmonary arterial hypertension (PAH) is a disease in which stenosis or obstruction of the pulmonary arteries (PAs) causes an increase in PA pressure, leading to right-sided heart failure and death. Basic research has revealed a decrease in the levels of endogenous vasodilators, such as prostacyclin, and an increase in the levels of endogenous vasoconstrictors, such as endothelin, in patients with PAH, leading to the development of therapeutic agents. Currently, therapeutic agents for PAH target three pathways that are selective for PAs: the prostacyclin, endothelin, and nitric oxide pathways. These treatments improve the prognosis of PAH patients. In this review, we introduce new drug therapies and provide an overview of the current therapeutic agents.

pharmacology & pharmacy,chemistry, medicinal
Pulmonary arterial hypertension nanotherapeutics: New pharmacological targets and drug delivery strategies

Hamza Boucetta,Lei Zhang,Alejandro Sosnik,Wei He

DOI: https://doi.org/10.1016/j.jconrel.2023.11.012

Abstract:Pulmonary arterial hypertension (PAH) is a rare, serious, and incurable disease characterized by high lung pressure. PAH-approved drugs based on conventional pathways are still not exhibiting favorable therapeutic outcomes. Drawbacks like short half-lives, toxicity, and teratogenicity hamper effectiveness, clinical conventionality, and long-term safety. Hence, approaches like repurposing drugs targeting various and new pharmacological cascades and/or loaded in non-toxic/efficient nanocarrier systems are being investigated lately. This review summarizes the status of conventional, repurposed, either in vitro, in vivo, and/or in clinical trials of PAH treatment. In-depth description, discussion, and classification of the new pharmacological targets and nanomedicine strategies with a description of all the nanocarriers that showed promising efficiency in delivering drugs are discussed. Ultimately, an illustration of the different nucleic acids tailored and nanoencapsulated within different types of nanocarriers to restore the pathways affected by this disease is presented.
Social and psychological factors affecting fertility. XXVIII. The influence of siblings and friends on fertility.

R. Potter,J. Kantner

DOI: https://doi.org/10.2307/3348292

1955-07-01

The Milbank Memorial Fund Quarterly

Abstract:
Combination therapy in the management of pulmonary arterial hypertension

M S Buckley,R L Staib,L M Wicks

DOI: https://doi.org/10.1111/ijcp.12136

Abstract:Background: Pulmonary arterial hypertension (PAH) is a progressive disease without a cure, which can lead to right heart failure and death. Over the past decades, several therapeutic advances have been developed for the management of PAH. Although these agents have demonstrated clinical safety and efficacy, some patients may require additional drug therapy due to a lack of response or disease progression. Aims: The purpose of this review was to evaluate the safety and efficacy of various combination PAH therapies. Materials & methods: A systematic search was conducted using the MEDLINE database (1966 and June 2012) for relevant clinical studies. Searches were limited to English, human and clinical trial using the terms sildenafil, tadalafil, vardenafil, phosphodiesterase inhibitor, prostacyclin, prostaglandin, epoprostenol, treprostinil, iloprost, beraprost, endothelin receptor antagonist, bosentan, ambrisentan, sitaxsentan and pulmonary hypertension. Results: Overall, 22 studies met inclusion criteria. Overall, the majority of trials demonstrated clinical efficacy in improving functional class, reducing pulmonary pressure, or increasing exercise capacity. Most trials were uncontrolled with small sample sizes investigating the acute effects of combination therapy and lacking long-term clinical outcomes. Adjunctive therapy was well tolerated by most patients. Discussion: Overall, combination therapy is relatively safe and well tolerated. Published guidelines provide evidence-based recommendations for monotherapy. However, suggestions for combination therapy in refractory PAH patients are lacking. Several studies evaluating several combination therapies have been published. The preferred combination treatment among several PAH drug therapies remain controversial. Therefore, clinicians should consider ease of administration, cost, and tolerability when choosing specific combination therapies. Conclusion: Combination therapy appears promising for patients who are refractory to treatment or whose disease progression is not well controlled with monotherapy. An optimal combination drug therapy regimen remains debatable and should be customized for individual PAH patients. Further studies are needed to determine the optimal combination therapy in PAH based upon efficacy, safety and cost.
Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.

N. Ruopp,B. Cockrill

DOI: https://doi.org/10.1001/jama.2022.4402

2022-04-12

Abstract:Importance Pulmonary arterial hypertension (PAH) is a subtype of pulmonary hypertension (PH), characterized by pulmonary arterial remodeling. The prevalence of PAH is approximately 10.6 cases per 1 million adults in the US. Untreated, PAH progresses to right heart failure and death. Observations Pulmonary hypertension is defined by a mean pulmonary artery pressure greater than 20 mm Hg and is classified into 5 clinical groups based on etiology, pathophysiology, and treatment. Pulmonary arterial hypertension is 1 of the 5 groups of PH and is hemodynamically defined by right heart catheterization demonstrating a mean pulmonary artery pressure greater than 20 mm Hg, a pulmonary artery wedge pressure of 15 mm Hg or lower, and a pulmonary vascular resistance of 3 Wood units or greater. Pulmonary arterial hypertension is further divided into subgroups based on underlying etiology, consisting of idiopathic PAH, heritable PAH, drug- and toxin-associated PAH, pulmonary veno-occlusive disease, PAH in long-term responders to calcium channel blockers, and persistent PH of the newborn, as well as PAH associated with other medical conditions including connective tissue disease, HIV, and congenital heart disease. Early presenting symptoms are nonspecific and typically consist of dyspnea on exertion and fatigue. Currently approved therapy for PAH consists of drugs that enhance the nitric oxide-cyclic guanosine monophosphate biological pathway (sildenafil, tadalafil, or riociguat), prostacyclin pathway agonists (epoprostenol or treprostinil), and endothelin pathway antagonists (bosentan and ambrisentan). With these PAH-specific therapies, 5-year survival has improved from 34% in 1991 to more than 60% in 2015. Current treatment consists of combination drug therapy that targets more than 1 biological pathway, such as the nitric oxide-cyclic guanosine monophosphate and endothelin pathways (eg, ambrisentan and tadalafil), and has shown demonstrable improvement in morbidity and mortality compared with the previous conventional single-pathway targeted monotherapy. Conclusions and Relevance Pulmonary arterial hypertension affects an estimated 10.6 per 1 million adults in the US and, without treatment, typically progresses to right heart failure and death. First-line therapy with drug combinations that target multiple biological pathways are associated with improved survival.

Medicine
Future Perspectives of Pulmonary Arterial Hypertension: A Review of Novel Pipeline Treatments and Indications

Maria Eugenia Novara,Enrica Di Martino,Brandon Stephens,Mary Nayrouz,Patrizio Vitulo,Anna Carollo,Alessio Provenzani

DOI: https://doi.org/10.1007/s40268-024-00453-x

2024-03-24

Drugs in R&D

Abstract:Pulmonary arterial hypertension is characterized by elevated blood pressure and pathological changes in the pulmonary arterioles, leading to the development of right-heart failure and potentially fatal outcomes if left untreated. This review aims to provide an overview of novel drugs or formulations and new drug indications for pulmonary arterial hypertension that are currently in phases II–III of randomized controlled trials, and describe the rationale for the use of these targeted therapies, as well as their efficacy, safety profile, and impact on quality of life and survival. The literature research was conducted using data from ClinicalTrials.gov for the period between 1 January 2016 up to 31 December 2022. The population of interest includes individuals aged ≥ 18 years who have been diagnosed with pulmonary arterial hypertension. The review selection criteria included trials with recruiting , enrolling by invitation, active, terminated or completed status in 2022 and 2023. A total of 24 studies were selected for evaluation based on the inclusion and exclusion criteria. This review summarizes the updated information from randomized clinical trials involving novel therapies for pulmonary arterial hypertension. However, larger clinical trials are required to validate their clinical safety and effects. In the future, clinicians should choose therapies based on the patient's individual situation and requirements when developing treatment strategies.

pharmacology & pharmacy
A Systematic Review of Novel Therapies of Pulmonary Arterial Hypertension

Omnia Azmy Nabeh,Alaa I Saud,Basma Amin,Amira Samy Khedr,Alaa Amr,Aml Medhat Faoosa,Eshraka Esmat,Yasmeen Magdy Mahmoud,Aya Hatem,Mariam Mohamed,Alaa Osama,Youssef Mohamed Amin Soliman,Reem Ibrahim Elkorashy,Soha Aly Elmorsy

DOI: https://doi.org/10.1007/s40256-023-00613-5

Abstract:Background: Pulmonary arterial hypertension (PAH) is a progressive, cureless disease, characterized by increased pulmonary vascular resistance and remodeling, with subsequent ventricular dilatation and failure. New therapeutic targets are being investigated for their potential roles in improving PAH patients' symptoms and reversing pulmonary vascular pathology. Method: We aimed to address the available knowledge from the published randomized controlled trials (RCTs) regarding the role of Rho-kinase (ROCK) inhibitors, bone morphogenetic protein 2 (BMP2) inhibitors, estrogen inhibitors, and AMP-activated protein kinase (AMPK) activators on the PAH evaluation parameters. This systematic review (SR) was registered in the International Prospective Register of Systematic Reviews (PROSPERO) database (CDR42022340658) and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Results: Overall, 5092 records were screened from different database and registries; 8 RCTs that met our inclusion criteria were included. The marked difference in the study designs and the variability of the selected outcome measurement tools among the studies made performing a meta-analysis impossible. However, the main findings of this SR relate to the powerful potential of the AMPK activator and the imminent antidiabetic drug metformin, and the BMP2 inhibitor sotatercept as promising PAH-modifying therapies. There is a need for long-term studies to evaluate the effect of the ROCK inhibitor fasudil and the estrogen aromatase inhibitor anastrozole in PAH patients. The role of tacrolimus in PAH is questionable. The discrepancy in the hemodynamic and clinical parameters necessitates defining cut values to predict improvement. The differences in the PAH etiologies render the judgment of the therapeutic potential of the tested drugs challenging. Conclusion: Metformin and sotatercept appear as promising therapeutic drugs for PAH. Clinical trials registration: This work was registered in PROSPERO (CDR42022340658).
Advances in the potential of nebulized inhalation for the treatment of pulmonary arterial hypertension

Miao Lu,Yang-Jin Baima,Zhu Ni,Li Yang,Song-Shan Zhang,Yun-Tao Zhang

DOI: https://doi.org/10.1016/j.cpcardiol.2024.102752

Abstract:Pulmonary hypertension is a pathophysiologic manifestation of a heterogeneous group of diseases, with the main pathophysiologic mechanisms being persistent pulmonary vasoconstriction and irreversible vascular remodeling. The impact significantly affects the prognosis of patients with pulmonary hypertension. If it is not treated and intervened in time, it may lead to right ventricular failure and further endanger the patient's life. Within the past decade or so, nebulized inhalation therapy is considered to have advantages in the treatment of pulmonary hypertension as a safe, limited, and rapid therapy, for example, inhaled vasodilators (prostate analogs, nitroglycerin, carbon monoxide analogs sildenafil, and nitroprusside), inhaled anti-inflammatory and antiproliferative agents (simvastatin, and selatinib), and inhaled peroxides (levocetirizine) have been recognized as emerging therapeutic approaches in the treatment of pulmonary hypertension as emerging therapeutic approaches. Therefore, this article provides a brief review of recent advances in the potential of nebulized inhaled vasodilators, anti-inflammatory and antiproliferative agents, and anti-peroxides for the treatment of pulmonary hypertension, with the aim of providing different therapeutic options for the treatment of pulmonary hypertension, enhancing the quality of survival, alleviating symptoms, and improving the prognosis of patients with this condition.
Highly selective and sensitive chromo-fluorogenic detection of the Tetryl explosive using functional silica nanoparticles.

Y. Salinas,Y. Salinas,E. Climent,E. Climent,R. Martínez‐Máñez,R. Martínez‐Máñez,F. Sancenón,F. Sancenón,M. Marcos,M. Marcos,J. Soto,A. Costero,A. Costero,S. Gil,S. Gil

DOI: https://doi.org/10.1039/c1cc14877j

IF: 4.9

2011-10-25

Chemical Communications

Abstract:Silica nanoparticles containing polyamines and thiol groups have been used as probes for the selective detection of Tetryl.
Pulmonary Hypertension: A Contemporary Review

Shelsey Johnson,Natascha Sommer,Katherine Cox-Flaherty,Norbert Weissmann,Corey E Ventetuolo,Bradley A Maron

DOI: https://doi.org/10.1164/rccm.202302-0327SO

2023-09-01

Abstract:Major advances in pulmonary arterial hypertension, pulmonary hypertension (PH) associated with lung disease, and chronic thromboembolic PH cast new light on the pathogenetic mechanisms, epidemiology, diagnostic approach, and therapeutic armamentarium for pulmonary vascular disease. Here, we summarize key basic, translational, and clinical PH reports, emphasizing findings that build on current state-of-the-art research. This review includes cutting-edge progress in translational pulmonary vascular biology, with a guide to the diagnosis of patients in clinical practice, incorporating recent PH definition revisions that continue emphasis on early detection of disease. PH management is reviewed including an overview of the evolving considerations for the approach to treatment of PH in patients with cardiopulmonary comorbidities, as well as a discussion of the groundbreaking sotatercept data for the treatment of pulmonary arterial hypertension.

Antibiotic substances from Basidiomycetes+. VII. Clitocybe illudens.

[Molecular weight characteristics of the proteins of oocytes and of cleavage ova in CBA mice by means of capillary microdisc electrophoresis].

New and Emerging Therapeutic Drugs for the Treatment of Pulmonary Arterial Hypertension: A Systematic Review

Mechanisms and treatment of pulmonary arterial hypertension

Risk stratification and medical therapy of pulmonary arterial hypertension

Medical Management of Pulmonary Arterial Hypertension: Current Approaches and Investigational Drugs

The Future of PAH Treatment

Endothelial Progenitor Cell-Based Therapy for Pulmonary Arterial Hypertension

Pharmacological Update and Emerging Treatments of Pulmonary Hypertension

Pulmonary arterial hypertension: pharmacologic therapies and potential pulmonary artery denervation treatment.

Pulmonary Hypertension: Pharmacological and Non-Pharmacological Therapies

Recent Advances in the Treatment of Pulmonary Arterial Hypertension

Pulmonary arterial hypertension nanotherapeutics: New pharmacological targets and drug delivery strategies

Social and psychological factors affecting fertility. XXVIII. The influence of siblings and friends on fertility.

Combination therapy in the management of pulmonary arterial hypertension

Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.

Future Perspectives of Pulmonary Arterial Hypertension: A Review of Novel Pipeline Treatments and Indications

A Systematic Review of Novel Therapies of Pulmonary Arterial Hypertension

Advances in the potential of nebulized inhalation for the treatment of pulmonary arterial hypertension

Highly selective and sensitive chromo-fluorogenic detection of the Tetryl explosive using functional silica nanoparticles.

Pulmonary Hypertension: A Contemporary Review